Trial Profile
Phase A Phase 2 Study Evaluating Response and Biomarkers in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer Treated With Nivolumab in Combination With Relatlimab
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Mar 2024
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Relatlimab (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- 18 Mar 2024 Planned primary completion date changed from 1 Feb 2025 to 23 May 2024.
- 18 Mar 2024 Status changed from recruiting to active, no longer recruiting.
- 01 Feb 2024 Planned End Date changed from 1 Feb 2024 to 1 Feb 2025.